Skip to main content
. 2022 Aug 23;13:954235. doi: 10.3389/fimmu.2022.954235

Figure 1.

Figure 1

Challenges of efficacy of CAR T cell therapy. Limited efficacy of CAR T cell therapy in haematological malignancies can be attributed to poor persistence of CAR T cells, antigen modulation and intrinsic resistance to death signalling of tumour cells and immunosuppressive microenvironment.